Lee Gravatt Wilke Bio: Dr. Lee Gravatt Wilke is the, Interim Chair of the Division of General Surgery, the Director of the University of Wisconsin Health Breast Center in Madison, WI and a Professor of Surgery. She received her undergraduate and medical degrees from Duke University. From 1993 to 2000, Dr Wilke attended the University of Michigan for her surgical residency. In 2000, Dr. Wilke returned to Duke and during her ten years as an Assistant and then Associate Professor, she developed a large breast cancer surgical program, assisted in the organization of the high risk and novel survivorship clinics and collaborated with several basic researcher teams to bring innovative treatments and interventions to human clinical trials.
In 2010 Dr Wilke moved to Madison, WI as the Director of the UW Health Breast Center and established a strategic plan to rapidly expand the research and clinical programs. Dr Wilke is currently the chair of the Research committee for the American Society of Breast Surgeons as well as the Principal Investigator for the UW NCTN Lead Academic Site clinical trials program. In each of her regional and national roles she is working with teams to identify groundbreaking research on breast cancer screening, treatment and follow-up. In addition to caring for breast cancer patients, Dr Wilke enjoys spending time with her husband, Nathan and 2 sons.
Fred T. Lee Jr, M.D. is a Professor of Radiology, Biomedical Engineering, and Urology, The Robert A. Turrel Professor of Imaging Science, and the Chief of Abdominal Intervention at the University of Wisconsin. He previously served as the Chief of Abdominal Imaging and Intervention, Chief of Oncologic Imaging, and Senior Vice Chair at the University of Wisconsin Department of Radiology. He received his bachelor of arts magna cum laude and medical degrees from the Six-Year Medical Program at Boston University, completed an internship in surgery at the University of Massachusetts, and received his radiology training at the University of Rochester, Rochester, NY. He has been a University of Wisconsin faculty member since 1991, and was designated as a Radiologic Society of North America Scholar in 1996.
While completing the requirements for the RSNA Scholars program, Dr. Lee developed an interest in minimally-invasive tumor ablation therapy, leading him to establish the Tumor Ablation Laboratory at the University of Wisconsin in 1995, one of the first of its type in the world. His work has resulted in over 200 scientific publications, hundreds of scientific and business presentations, 20 book chapters, 24 inventions/patents, and substantial federal and industrial grant support. He is the recipient of more than 50 major honors and awards including multiple “Best Doctor” awards, the UW Health Presidential Physician Leadership Award, and the Grand Prize in the 2014 Wisconsin Governor’s Business Plan Competition for Elucent Medical, Inc. As a serial entrepreneur, Dr. Lee is a founding member of three venture-backed biotech start-up companies devoted to cancer treatment: Cellectar, Inc. (Madison, WI), NeuWave Medical Inc. (Madison, WI a member of the Ethicon and Johnson & Johnson family of companies), and Elucent Medical, Inc. (Minneapolis, MN), the latter two companies co-founded with Dr. van der Weide and Ms. King. NeuWave Medical was sold to Ethicon (Johnson & Johnson) in May 2016, and Dr. Lee remains as a consultant. In addition to being a company founder, Dr. Lee currently serves on the board of directors and as Senior Medical Advisor for Histosonics, Inc., a University of Michigan startup company developing a non-invasive, non-thermal focused ultrasound technology for tissue destruction.
Professor Dan van der Weide is co-founder, Chief Technical Officer and member of the Board of Directors at Elucent Medical. He co-founded NeuWave Medical and Optametra, both of which had successful exits, and continues to be involved in early-stage ventures, both as a founder and as an advisor.
Ms. King is Founder and CEO of Elucent Medical, a company that has developed a medical device to locate breast tumors in surgery while concurrently eliminating a painful and expensive wire localization procedure from breast cancer treatment.
Prior to Elucent, Ms. King led NeuWave Medical, a Madison, WI based start-up that developed and commercialized a device to ablate cancer tumors in liver, kidney, lung and bone. Ms. King led NeuWave Medical for seven years, successfully raising $33 M in venture capital and doubling revenue each year. NeuWave had a very successful exit, selling to JnJ Ethicon in 2016. Prior to joining the start-up world, Ms. King was a GE company officer while leading the $1.2 B Global Interventional Cardiology and Surgery business. Raised in San Francisco, CA, she is a graduate of UC Davis in Economics.